The Company’s corporate partnering strategy is to out-license our proprietary alphavaccine technology for specific disease and/or antigen applications for commercialization. The alphavaccine technology is based on AlphaVax’s proprietary replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus. Industry interest in the alphavaccine technology has increased as vaccine candidates move through the development pipeline.
AlphaVax currently has two corporate partners, Merck's Intervet subsidiary and Novartis Vaccines and Diagnostics, Inc., and has also licensed its technology to US government agencies for specific vaccine treatments against certain viruses.
The Company had initially licensed its technology to Harrisvaccines (now part of Merck Animal Health) for the development of vaccines for certain farmed animals and companion animals. Various vaccine products have been launched in the past four years. In return, the Company receives royalty payments on vaccine sales.
AlphaVax has also licensed a Cytomegalovirus (CMV) alphavaccine to Novartis Vaccines and Diagnostics, Inc. for its development and commercialization.
In the past few years, AlphaVax has entered into various exclusive licensing agreement with the Chemical Biological Medical Systems section of the U.S. Department of Defense for the development of alphavaccines for the Filoviruses: Marburg and Ebola and other viruses.
Other agreements entered into over the past three years remain confidential.